BNP Paribas Financial Markets Has $301,000 Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

BNP Paribas Financial Markets cut its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 83.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 6,754 shares of the company's stock after selling 33,417 shares during the quarter. BNP Paribas Financial Markets' holdings in Omnicell were worth $301,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of OMCL. KBC Group NV grew its holdings in shares of Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company's stock worth $92,000 after acquiring an additional 778 shares during the last quarter. SteelPeak Wealth LLC acquired a new position in shares of Omnicell in the 4th quarter worth $635,000. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after acquiring an additional 699,925 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of Omnicell in the 4th quarter worth $388,000. Finally, Shaker Investments LLC OH acquired a new position in shares of Omnicell in the 4th quarter worth $550,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Bank of America lifted their price target on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. Wall Street Zen upgraded Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, May 20th. JPMorgan Chase & Co. lowered their price target on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. Finally, Benchmark lowered their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Omnicell has a consensus rating of "Moderate Buy" and a consensus price target of $44.83.

Omnicell Stock Performance

NASDAQ:OMCL traded up $0.39 during mid-day trading on Friday, hitting $30.22. 756,716 shares of the company's stock traded hands, compared to its average volume of 569,878. The firm has a 50 day moving average of $30.42 and a two-hundred day moving average of $37.96. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.75. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 111.93, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. During the same quarter in the prior year, the company earned $0.03 EPS. The firm's revenue for the quarter was up 9.5% compared to the same quarter last year. On average, equities analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.